PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
Background and aimsProprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in cholesterol homeostasis by regulating low-density lipoprotein (LDL) receptor levels. Despite its known effects on cholesterol metabolism, the role of PCSK9 in cardiac function, especially post-myocardial...
Saved in:
Main Authors: | Simon Rauterberg, Carmen Härdtner, Jennifer Hein, Paola Schrepf, Remi Peyronnet, Christoph Koentges, Tamara A. Vico, Carolin Ehlert, Bianca Dufner, Diana Lindner, Constantin von zur Mühlen, Dennis Wolf, Dirk Westermann, Ingo Hilgendorf, Alexander von Ehr |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1463844/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PCSK9 in T-cell function and the immune response
by: Yuying Wang, et al.
Published: (2024-12-01) -
Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice
by: Xue-Ying Zhang, et al.
Published: (2025-02-01) -
Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review
by: Ewelina Jakielska, et al.
Published: (2023-03-01) -
Mutual mediation effects of homocysteine and PCSK9 on coronary lesion severity in patients with acute coronary syndrome: interplay with inflammatory and lipid markers
by: Ping Jin, et al.
Published: (2025-01-01) -
Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis
by: Yuhua Jiang, et al.
Published: (2025-02-01)